Advertisement

Expert Point of View: Catherine C. Park, MD, FASTRO


Advertisement
Get Permission

Catherine C. Park, MD, FASTRO

Catherine C. Park, MD, FASTRO

DISCUSSANT OF the abstract, Catherine C. Park, MD, FASTRO, Professor and Chair of the Department of Radiation Oncology at the University of California, San Francisco, expressed excitement about this study’s results, which suggest the possibility of curing patients with stage IV disease.

“We’re seeing the increasing relevance of local regional treatment in many emerging paradigms,” said Dr. Park. “With the onset of more effective chemotherapies, systemic therapies, and biologics that can eradicate distant disease effectively, disease that remains local and is still responsive—but for which chemotherapy is not quite enough—seems like a great opportunity for radiation therapy.”

“I think we’ll see this theme more and more in terms of treating oligometastasis as we start to look at other disease sites and certainly with immune therapy now here to stay,” Dr. Park added. “There are multiple opportunities to be thinking about how radiation as a local therapy can impact a systemic disease and cure.”

DISCLOSURE: Dr. Park reported no conflicts of interest.


Related Articles

Local Consolidative Therapy Associated With Survival Benefit for Some With Oligometastatic NSCLC

FOR A SUBSET of patients with stage IV lung cancer, aggressive treatment may improve overall survival, according to data presented at the 2018 Annual Meeting of the American Society for Radiation Oncology (ASTRO).1

The results of the phase II study showed that with long-term follow-up, local...

Advertisement

Advertisement



Advertisement